AMGN Amgen Inc

Filed Pursuant to Rule 433

Registration Statement 333-236351

February 18, 2020

Amgen Inc.

PRICING TERM SHEET

Dated February 18, 2020

$500,000,000 1.900% Senior Notes due 2025 (the “2025” Notes)

$750,000,000 2.200% Senior Notes due 2027 (the “2027” Notes)

$1,250,000,000 2.450% Senior Notes due 2030 (the “2030” Notes)

$1,250,000,000 3.150% Senior Notes due 2040 (the “2040” Notes)

$1,250,000,000 3.375% Senior Notes due 2050 (the “2050” Notes)

This term sheet relates only to the securities described below and supplements and should be read together with the preliminary prospectus supplement, dated February 18, 2020, and the accompanying prospectus (including the documents incorporated by reference in the accompanying prospectus) relating to these securities.

1

Changes to Preliminary Prospectus Supplement

The second paragraph of the section entitled “Use of Proceeds” is revised in its entirety to read as set forth below. (Additional conforming changes will be made to the Preliminary Prospectus Supplement consistent with these changes.)

“We intend to use the net proceeds from this offering to (i) redeem in full our outstanding 3.45% Senior Notes due 2020 in an aggregate outstanding principal amount of $900 million, which have a stated maturity date of October 1, 2020, (ii) redeem in full our 4.10% Senior Notes due 2021 in an aggregate outstanding principal amount of $1.0 billion, which have a stated maturity date of June 15, 2021, (iii) redeem in full our 1.85% Senior Notes due 2021 in an aggregate outstanding principal amount of $750 million, which have a stated maturity date of August 19, 2021 and (iv) redeem $300 million aggregate principal amount of our 3.875% Senior Notes due 2021 (of which $1.75 billion aggregate principal amount of such Notes is currently outstanding), which have a stated maturity date of November 15, 2021. The redemption of each series of notes will include the payment of a make-whole amount and accrued and unpaid interest on the notes to, but not including, the date of redemption. We intend to use any remaining net proceeds from this offering to repay our outstanding indebtedness and for general corporate purposes.”

Amgen Inc. has filed a registration statement (including a prospectus dated as of February 10, 2020) and a prospectus supplement dated as of February 18, 2020 with the SEC for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement, the prospectus supplement and other documents Amgen Inc. has filed with the SEC for more complete information about the issuer and this offering. You should rely on the prospectus, prospectus supplement and any relevant free writing prospectus or term sheet for complete details. You may get these documents for free by visiting the SEC web site at www.sec.gov. Alternatively, copies of the prospectus and the prospectus supplement may be obtained from (i) Citigroup Global Markets Inc. toll-free at 1-800-831-9146, (ii) Goldman Sachs & Co. LLC. toll-free at 1-866-471-2526, (iii) Barclays Capital Inc. toll-free at 1-888-603-5847 and (iv) Morgan Stanley & Co. LLC toll-free at 1-866-718-1649.

Any disclaimer or other notice that may appear below is not applicable to this communication and should be disregarded (other than any statement relating to the identity of the legal entity authorizing or sending this communication in a non-US jurisdiction). Such disclaimer or notice was automatically generated as a result of this communication being sent by Bloomberg or another e-mail system.

3